×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RYTM – rhythm pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RYTM
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/7
04:11 pm
rytm
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at Wells Fargo & Company from $80.00 to $91.00. They now have an "overweight" rating on the stock.
Low
Report
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at Wells Fargo & Company from $80.00 to $91.00. They now have an "overweight" rating on the stock.
4/7
01:11 pm
rytm
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) was upgraded by analysts at Bank of America Co. from a "neutral" rating to a "buy" rating. They now have a $63.00 price target on the stock.
Medium
Report
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) was upgraded by analysts at Bank of America Co. from a "neutral" rating to a "buy" rating. They now have a $63.00 price target on the stock.
4/7
12:43 pm
rytm
Obesity drug data helps Rhythm defy market slide [Yahoo! Finance]
Low
Report
Obesity drug data helps Rhythm defy market slide [Yahoo! Finance]
4/7
07:24 am
rytm
Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity [Yahoo! Finance]
High
Report
Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity [Yahoo! Finance]
4/7
07:00 am
rytm
Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity
High
Report
Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity
4/6
12:00 pm
rytm
Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity
High
Report
Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity
3/24
08:09 am
rytm
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
Medium
Report
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
3/20
08:08 pm
rytm
Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd. [Yahoo! Finance]
Low
Report
Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd. [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
2/26/2025
07:00 am
RYTM
rhythm pharmaceuticals, inc.
MISS
Report
0.1%
rhythm pharmaceuticals, inc.
2/26/2025
07:00 am
RYTM
rhythm pharmaceuticals, inc.
MISS
Report
1.0%
rhythm pharmaceuticals, inc.
2/26/2025
07:00 am
RYTM
rhythm pharmaceuticals, inc.
MISS
Report
1.0%
rhythm pharmaceuticals, inc.
2/26/2025
07:00 am
RYTM
rhythm pharmaceuticals, inc.
MISS
Report
1.0%
rhythm pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/7
07:01 am
rytm
Form 8-K RHYTHM PHARMACEUTICALS, For: Apr 07
High
Report
Form 8-K RHYTHM PHARMACEUTICALS, For: Apr 07
3/24
05:48 pm
rytm
Form 4 RHYTHM PHARMACEUTICALS, For: Mar 20 Filed by: German Christopher Paul
Low
Report
Form 4 RHYTHM PHARMACEUTICALS, For: Mar 20 Filed by: German Christopher Paul
3/20
04:05 pm
rytm
Form 8-K RHYTHM PHARMACEUTICALS, For: Mar 14
Medium
Report
Form 8-K RHYTHM PHARMACEUTICALS, For: Mar 14
3/18
09:17 pm
rytm
Form 4 RHYTHM PHARMACEUTICALS, For: Mar 14 Filed by: Mazabraud Yann
Medium
Report
Form 4 RHYTHM PHARMACEUTICALS, For: Mar 14 Filed by: Mazabraud Yann
3/14
04:21 pm
rytm
Form 144 RHYTHM PHARMACEUTICALS, Filed by: Mazabraud Yann
Low
Report
Form 144 RHYTHM PHARMACEUTICALS, Filed by: Mazabraud Yann
2/28
04:01 pm
rytm
Form S-8 RHYTHM PHARMACEUTICALS,
Medium
Report
Form S-8 RHYTHM PHARMACEUTICALS,
2/28
08:21 am
rytm
Form 8-K RHYTHM PHARMACEUTICALS, For: Feb 27
Medium
Report
Form 8-K RHYTHM PHARMACEUTICALS, For: Feb 27
2/28
08:19 am
rytm
Form 10-K RHYTHM PHARMACEUTICALS, For: Dec 31
Medium
Report
Form 10-K RHYTHM PHARMACEUTICALS, For: Dec 31
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
8/7
Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency Obesities
14.9%
3/16 Form 4 RHYTHM PHARMACEUTICALS, For: Mar 13 Filed by: Smith Hunter C 14.5%
10/15 Form 8-K RHYTHM PHARMACEUTICALS, For: Oct 15 13.4%
10/18 Form 3 RHYTHM PHARMACEUTICALS, For: Oct 16 Filed by: RA Capital Healthcare Fund LP 10.2%
4/9 Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 10.0%
11/22 Form 4 RHYTHM PHARMACEUTICALS, For: Nov 20 Filed by: Foley Todd 6.3%
3/2 Q4/2019 12/31/2019 EPS -0.780 ZacksConsensus N/A ActVsEst N/A - N/A 6.2%
12/5 Rhythm Pharmaceuticals Completes Enrollment of Pivotal Cohort in Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes 6.0%
2/25 Rhythm Pharmaceuticals to Present at Cowen & Co. 40th Annual Health Care Conference 5.5%
3/30 Rhythm Pharmaceuticals Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Setmelanotide in POMC and LEPR Deficiency Obesities 5.1%
3/16 Form 4 RHYTHM PHARMACEUTICALS, For: Mar 13 Filed by: Smith Hunter C 14.5%
10/15 Form 8-K RHYTHM PHARMACEUTICALS, For: Oct 15 13.4%
10/18 Form 3 RHYTHM PHARMACEUTICALS, For: Oct 16 Filed by: RA Capital Healthcare Fund LP 10.2%
4/9 Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 10.0%
11/22 Form 4 RHYTHM PHARMACEUTICALS, For: Nov 20 Filed by: Foley Todd 6.3%
3/2 Q4/2019 12/31/2019 EPS -0.780 ZacksConsensus N/A ActVsEst N/A - N/A 6.2%
12/5 Rhythm Pharmaceuticals Completes Enrollment of Pivotal Cohort in Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes 6.0%
2/25 Rhythm Pharmaceuticals to Present at Cowen & Co. 40th Annual Health Care Conference 5.5%
3/30 Rhythm Pharmaceuticals Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Setmelanotide in POMC and LEPR Deficiency Obesities 5.1%
TOP News Decliners
8/7
Form 8-K RHYTHM PHARMACEUTICALS, For: Aug 07
-9.8%
9/25 Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $40.00 price target on the stock. -8.5%
1/10 Form 8-K RHYTHM PHARMACEUTICALS, For: Jan 10 -5.1%
2/26 Form 8-K RHYTHM PHARMACEUTICALS, For: Feb 20 -5.0%
4/30 Form 4 RHYTHM PHARMACEUTICALS, For: Apr 28 Filed by: Foley Todd -4.7%
4/29 Form DEF 14A RHYTHM PHARMACEUTICALS, For: Jun 17 -4.7%
3/18 Rhythm Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for Setmelanotide for the Treatment of Alström Syndrome -4.6%
7/29 Rhythm Pharmaceuticals Reports Second Quarter 2019 Financial Results -4.2%
6/21 Form 3 RHYTHM PHARMACEUTICALS, For: Jun 19 Filed by: GOOD JENNIFER L -4.1%
1/6 Rhythm Pharmaceuticals Announces Leadership Transition -4.1%
9/25 Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $40.00 price target on the stock. -8.5%
1/10 Form 8-K RHYTHM PHARMACEUTICALS, For: Jan 10 -5.1%
2/26 Form 8-K RHYTHM PHARMACEUTICALS, For: Feb 20 -5.0%
4/30 Form 4 RHYTHM PHARMACEUTICALS, For: Apr 28 Filed by: Foley Todd -4.7%
4/29 Form DEF 14A RHYTHM PHARMACEUTICALS, For: Jun 17 -4.7%
3/18 Rhythm Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for Setmelanotide for the Treatment of Alström Syndrome -4.6%
7/29 Rhythm Pharmaceuticals Reports Second Quarter 2019 Financial Results -4.2%
6/21 Form 3 RHYTHM PHARMACEUTICALS, For: Jun 19 Filed by: GOOD JENNIFER L -4.1%
1/6 Rhythm Pharmaceuticals Announces Leadership Transition -4.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: